

**AMENDMENTS TO THE SPECIFICATION**

*Please amend the specification as follows:*

*Please replace the title of the application at page 1, line 1 of the specification with the following title:*

**TREATMENT OF PSORIASIS USING TNF $\alpha$  ANTIBODIES ~~TNF $\alpha$ -RELATED DISORDERS~~**

*Please replace the “Related Applications” section of the specification at page 1, line 16 to page 2, line 2 with the following replacement section:*

-- This application is related to U.S. utility applications 10/623039 entitled “Treatment of Spondyloarthropathies Using TNF $\alpha$  Inhibitors,” 10/623076 (now abandoned) entitled “Treatment of Pulmonary Disorders Using TNF $\alpha$  Inhibitors,” 10/623065 (now abandoned) entitled “Treatment of Coronary Disorders Using TNF $\alpha$  Inhibitors,” 10/622928 (now abandoned) entitled “Treatment of Metabolic Disorders Using TNF $\alpha$  Inhibitors,” 10/623075 (now abandoned) entitled “Treatment of Anemia Using TNF $\alpha$  Inhibitors,” 10/623035 (now abandoned) entitled “Treatment of Pain Using TNF $\alpha$  Inhibitors,” 10/622683 (now abandoned) entitled “Treatment of Hepatic Disorders Using TNF $\alpha$  Inhibitors,” 10/622205 (now abandoned) entitled “Treatment of Skin and Nail Disorders Using TNF $\alpha$  Inhibitors,” 10/622210 (now abandoned) entitled “Treatment of Vasculitides Using TNF $\alpha$  Inhibitors,” 10/623318 entitled “Treatment of TNF $\alpha$ -Related Disorders Using TNF $\alpha$  Inhibitors,” and PCT application PCT/US2003/022566 entitled “Treatment of TNF $\alpha$ -Related Disorders,” all of which are filed on even date herewith. The entire contents of each of these patents and patent applications are hereby incorporated herein by reference.